The metabolic mechanisms underlying aristolochic acid (AA)-induced nephrotoxicity are inconclusive. A Gas ChromatographyMass Spectrometer (GC-MS)-based metabolomic study was performed to analyze urinary metabolites in AA-treated rats at different dosages (10, 20, and 40 mg/kg) and time points (2, 4, and 6 days). Serum blood urea nitrogen (BUN), creatinine, and kidney injury were significantly changed only on the 6th day in 40 mg/kg AA group, whereas metabolic alternation appeared even on the 2nd day in 10 mg/kg AA group. A total of 84 differential metabolites were identified in 40 mg/kg AA groups timedependently and 81 in 10, 20, and 40 mg/kg AA groups dose-dependently (6 days) compared with control group. Eight metabolites were selected as potential metabolic biomarkers including methylsuccinic acid, nicotinamide, 3-hydroxyphenylacetic acid, citric acid, creatinine, uric acid, glycolic acid, and gluconic acid. Four of them were dose-dependently altered including methylsuccinic acid, citric acid, creatinine, and 3-hydroxyphenylacetic acid, which were defined as "early metabolic biomarker." The alteration of nicotinamide, uric acid, and gluconic acid was time-and dose-dependent, whereas the change of glycolic acid was time-or doseindependent. The latter 4 metabolites were defined as "late metabolic biomarker" because of the obvious reduction on the 6th day in 40 mg/kg AA group. In summary, the urinary metabolic alterations were more sensitive than conventional biomarkers of renal injury. The identified metabolites suggested pathways of energy metabolism, gut microbiota, and purine metabolism were associated with AA-induced nephrotoxicity time-or dose-dependently. Further investigation was warranted to determine the roles of the 8 potential metabolic biomarkers in AA-induced nephrotoxicity.
Aristolochic acid (AA) is a mixture of structurally related nitrophenanthrene carboxylic acids such as AA I and AA II (Yeh et al., 2008) . Herbal medicines in Aristolochia genus containing AA have long been used for treatment of various diseases (Heinrich et al., 2009) . AA exposure could raise the risk of upper urinary tract carcinoma, heat failure, and severe anemia Huang et al., 2007; Nortier et al., 2000 Nortier et al., , 2015 Nortier and Vanherweghem, 2002) . AA-induced nephrotoxicity has come into light due to the occurrence of acute renal failure in several Belgian women who took the medicinal herbs containing AA for slimming (Vanherweghem et al., 1993) . Evidence indicates that there is a large-scale of exposure to AA in Asia leading to high risk of public health (Gokmen and Lord, 2012) . Approximately 78 644 patients from a randomly sampled cohort consisting of 200 000 patients were prescribed with AA-containing Chinese herbal products from 1997 to 2003 according to the data from National Health Insurance in Taiwan . A strong association has been observed between consumption of herbal medicines containing AA and cancer of upper urinary tract and bladder (Li et al., 2005) . As a result, AA-induced nephrotoxicity and its resulting diseases are severe threat to public health.
AA-induced nephrotoxicity is usually marked by elevated serum creatinine and kidney injury molecule-1, and is accompanied by histopathologic changes, which may result in chronic kidney disease or quickly progress into the end-stage renal disease (Luciano and Perazella, 2015; Sabbisetti et al., 2013) . Experimental evidence indicated that kidney proximal tubule was the primary target in AA-induced nephrotoxicity, which is associated with the change in mitochondrial permeability (Qi et al., 2007) , transformation of epithelial to mesenchymal cells (Pozdzik et al., 2008; Wang et al., 2010; Zhou et al., 2010) , as well as AA-DNA adducts (Allard et al., 2013; Arlt et al., 2001; Jha, 2010) . A nuclear magnetic resonance-based study also indicated that 10 mg/kg AA treatment on rats for 5 days elicited renal papillary lesion accompanied with mild hepatic damage (Zhang et al., 2006) . Lou et al. (2011) reported that 10 and 20 mg AA treatment for 7 days resulted in the destruction of organic ion transporters and dysfunction of fatty acid metabolism in kidney tissues contributing to nephrotoxicity. Li et al. (2012) reported that AA treatment resulted in the accumulation of methylglyoxal, a highly cytotoxic metabolite derived from glucose and fatty acids metabolism. The over produced methylglyoxal binds to proteins and forms Ne-(carboxymethyl)lysine leading to kidney damage.
Although the molecular mechanisms have been extensively reported, the metabolomics-based investigations are attracting more attentions in recent years because of the advantages of metabolomics in capturing comprehensive and dynamic metabolic impacts of AA treatment. Chen et al. (2006) observed the continued metabolic changes within 6 days after a single dose of 50 mg/kg AA in rats by analyzing the urine samples with LC-MS. They found a single dose of AA increased the levels of homocysteine and decreased arachidonic acid in urine (Chen et al., 2006) . Then, these samples were further analyzed by using combined Gas Chromatography-Mass Spectrometer (GC-MS) and Liquid Chromatograph-Mass Spectrometer (LC-MS). In addition to the consistent changes in homocysteine and arachidonic acid, they observed obvious variations in fatty acid and amino acid metabolism, as well as gut microbiota (Ni et al., 2007) . Chan et al. (2008) studied the urinary metabolic alterations in AA-treated rats using LC-QTOFMS and found that urinary citric acid and a glucuronide-containing metabolite might serve as potential markers for AA exposure. Recently, Zhao et al. (2015) investigated the time-dependent urinary biomarkers in AA-treated rats by using UPLC-QTOFMS, which were treated with 20 mg/kg AA I for 12 weeks at per week intervals. Their results suggested that AA-induced nephrotoxicity was associated with the metabolic alterations in tricarboxylic acid cycle (TCA) cycle, gut microbiota, amino acid, purine, and bile acid metabolism (Zhao et al., 2015) . These studies highlight the significance of metabolomic approach in uncovering the comprehensively and dynamically metabolic changes induced by AA. However, given the diversified dosages and time points of AA treatment, the metabolic characters of AA treatment are inconclusive.
In this study, we investigated the urinary time-(days 2, 4, and 6) or dose-(10, 20, and 40 mg/kg) dependent metabolic biomarkers for AA-induced nephrotoxicity by using GC-MS-based metabolic profiling in rats. Our current results showed that AA treatment induced transparent urinary metabolic alteration time-or dose-dependently. A total of 84 differential metabolites were identified in 40 mg/kg AA groups time-dependently and 81 in 10, 20, and 40 mg/kg AA groups dose-dependently (6 days) compared with control group. Eight metabolites were further selected as potential metabolic biomarkers including methylsuccinic acid, nicotinamide, 3-hydroxyphenylacetic acid, citric acid, creatinine, uric acid, glycolic acid, and gluconic acid. The identified metabolites suggested pathways of energy metabolism, gut microbiota, and purine metabolism were associated with AAinduced nephrotoxicity time-or dose-dependently.
MATERIALS AND METHODS
Animal treatment and sample collection. Fifty 6-week-old male Wistar rats were purchased from Shanghai Laboratory Animals Co, Ltd (SLAC, Shanghai, China) and randomly divided into 10 groups (N ¼ 5) as following: control group (Con), 10 mg/kg AA for 2 days (10D2), 4 days (10D4), and 6 days (10D6), 20 mg/kg AA for 2 days (20D2), 4 days (20D4), and 6 days (20D6), 40 mg/kg AA for 2 days (40D2), 4 days (40D4), and 6 days (40D6). All the animals were kept in a standard Specific Pathogen Free (SPF) level room with regulated temperature (22 C-26 C), relative humidity (30%-70%), and on a 12/12-h dark/light cycle. AA I (90% purity, No: A5512, Sigma-Aldrich) was diluted by PEG-400 (1:1), and the vehicle solution was a mixture of PEG-400 and water (1:1). The pH value was adjusted to 4.6-4.8. Low dose (10 mg/kg), medium dose (20 mg/kg), and high dose (40 mg/kg) of AA I solution were prepared at the concentration of 5, 10, and 20 mg/ml. After 1-week acclimation, rats in experimental groups were intraperitoneally treated with 10, 20, and 40 mg/kg body weight AA I (200 ll/ 100 g body weight), respectively, and the control rats were given same volume of vehicle. Animals were sacrificed according to the grouping, respectively. Serum was collected, stored at À80 C until further analysis. Urine samples were collected with icebathed tubes within the metabolic cages for continued 12 h before sacrifice. The collected urine samples were centrifuged at 13 000 Â g for 10 min, and the supernatant was stored À80 C until further analysis. Kidneys were kept in 10% formaldehyde solution for histological evaluation after H&E staining.
Sample preparation and GC-MS analysis. Twenty microliters of urine sample was transferred to an Eppendorf tube, and added with 20 ll of urease (1000 U/ml). The tubes were vortexed for 5 s, and kept at 37 C for 60 min. Then, 240 ll of ice-cold ethanol was added into the tubes, vortexed for 30 s, and kept at 4 C for 60 min. After that, the tubes were centrifuged at 14 000 Â g at 4 C for 15 min. A 224 ll of supernatant was collected into glass vial with 10 ll of internal standard (0.1 mg/ml dulcitol) and dried with N2. The residue of each sample was added with 30 ll of 20 mg/ml methoxylamine hydrochloride in pyridine, vortexed for 30 s, and incubated at 37 C for 90 min. Thirty microliters of N,O-bis(trimethylsilyl) trifluroacetamide (BSTFA) with 1% trimethylchlorosilane (TMCS) (Morton Grove, Illinois) was added into the mixture, vortexed 5 s, and incubated at 70 C for 60 min.
Four Quality Control (QC) samples were prepared and analyzed with the same procedure during the entire analysis. The derivatized samples were analyzed with Agilent 7890A gas chromatography coupled to an Agilent 5975C Mass-SpringDamper (MSD) system (Agilent, California) according to the method described in previous publication (Jin et al., 2014) with some minor modifications. Specifically, a HP-5MS capillary column (30 m Â 0.25 mm Â 0.25 lm, Agilent J&W Scientific, Folsom, California) was used for derivatives separation. The carrier gas Helium was set at a constant flow rate of 1 ml/min through the column with the injection volume of 1 ll, and the solvent delay time was 5.5 min. The initial oven temperature was held at 70 C for 2 min, ramped to 160 C at a rate of 6 C/min, then increased to 240 C at a rate of 10 C/min, and 300 C at a rate of 20 C/min, and finally kept at 300 C for 6 min. The temperature of the injector, transfer line, and ion source (electron impact) was set to 250 C, 290 C, and 230 C, respectively. The collision energy was 70 eV. Mass data was acquired in a full-scan mode (m/z 50 À 600). All the samples were analyzed in a random sequence.
Data processing and statistical analysis. The acquired GC/MS data were processed as described in previous publication (Jin et al., 2014) . Briefly, the sample information, peak retention time, and peak area (quant mass) were included in the final data set, in which the artificial peaks were removed such as peaks caused by noise, column bleed, and the BSTFA derivatization procedure. Then, the data were normalized to the total peak area of each sample with Excel 2010 (Microsoft), and the resulting data were imported into a SIMCA-P (version 11.0, Umetrics, Umeå , Sweden) for further analysis. The identification of urinary metabolites was performed according to the method (Jin et al., 2014) . Briefly, all data were mean-centered and unit variance-scaled in SIMCA-P. Unsupervised principal component analysis (PCA) was conducted for characterizing the metabolic profiles among groups, and supervised partial least squares discriminant analysis (PLS-DA) models were conducted for discriminating groups. The differential metabolites were selected with the criteria of variable importance in the projection ( Y is defined as the proportion of variance in the data explained by the models and indicates goodness of fit. Q 2 represents the proportion of variance in the data predicted by the model and indicates predictability calculated by a cross validation procedure. A default 7-round cross validation in SIMCA-P was performed to determine the optimal number of principal components and to avoid model overfitting.
Selection of potential metabolic biomarkers. On the basis of identified differential metabolites, a panel of potential metabolic biomarkers was determined according to the reference (Lee et al., 2016) . The criteria for selection of potential metabolic biomarkers include metabolites with the P values < .001 and the highest VIP scores in PLS-DA models.
RESULTS
The Time-and Dose-Dependent Renal Injury in AA-Treated Rats We found that the body weight gain of rats in both control and 10 mg/kg AA groups was similar, whereas reduced body weight was observed in 20D6, 40D2, 40D4, and 40D6 groups ( Figure 1A ). Significant increases in serum creatinine and BUN were only Table 1 ). On the 2nd day, the metabolic profiles were shifted dose-dependently, in which the control and 40 mg/kg groups were distinctly separated alongside the PC1, while the 10 and 20 mg/kg groups almost clustered together between control and 40 mg/kg groups (Figs. 3A and D), indicating that 40 mg/kg AA treatment resulted in obvious metabolic impacts on rats even on the 2nd day when conventional biomarkers were not present. Moreover, samples in 40 mg/kg group were greatly scattered either in PCA or PLS-DA models indicating variable responses to the short term high dose AA treatment (Figs. 3A and D) . On the 4th day, almost all samples from 3 AA groups were separated from control group by PC2, and the samples within AA groups were scattered alongside PC1 dose-dependently (Figs. 3B and E). On the 6th day, samples from 40 mg/kg group were clearly separated with the rest groups by PC1, while the control group was located between 10 and 20 mg/kg groups alongside the PC2 (Figs. 3C and F). Obvious interindividual variation was also observed in 40 mg/kg group, indicating the different responses to continued 6 days' high dose AA treatment ( Figure 3C ). Because the obvious kidney injury was only observed in 40D6 group according to conventional markers, the time-dependent metabolic impacts were investigated by comparing metabolites in 40D2, 40D4, and 40D6 groups to control group, respectively. A total of 47, 46, and 51 differential metabolites were identified in different time points compared with control group with VIP > 1 in PLS-DA model ( Figure 4A ). Among these differential metabolites, 21 of them were present only in 40D6 group, 6 in both 40D4 and 40D6 groups, and 18 in all 40 mg/kg AA groups, which were defined as time-dependent metabolites for further analysis ( Figure 4A) . Then, the dose-dependent effects of AA were shown by comparing metabolites in 10D6, 20D6, and 40D6 groups to control group, respectively, in which 39, 40, and 51 differential metabolites were observed with VIP > 1 in PLS-DA model ( Figure 4B ). Among these differential metabolites, 17 of them appeared only in 40D6 group, 14 of them in both 20D6 and 40D6 FIG. 1. Growth rate and serum biochemical markers. A, Relative body weight of rats treated with different dosages of aristolochic acid (AA) for 2, 4, and 6 days, respectively. B and C, Changes of serum biochemical markers (BUN and creatinine) in AA-treated groups and control group. D2, D4, and D6 represent rats were treated with AA for continued 2, 4, and 6 days, respectively. *P < .05 compared with control group. #1 P < .05 compared with 40D2 group. #2 P < .05 compared with 40D4 group. ᭞1 P < .05 compared with 10D6group. ᭞2 P < .05 compared with 20D6 group (N ¼ 5).
groups, and 8 in the all of the 3 groups, which were defined as dose-dependent differential metabolites for further analysis ( Figure 4B ). The variations of these time-or dose-dependent differential metabolites were visualized with heat maps described with 6 clusters (Figs. 4C-D) . Cluster I depicted the early metabolic disturbance appeared from the 2nd to 6th day in 40 mg/kg AAtreated groups. Most of them were downregulated, except for the significantly upregulated proline, glyceric acid, aminomalonic acid, creatinine, threonine, glutamine, and histidine. Leucine was the only upregulated metabolite among the 6 metabolites in cluster II. Four out of the 21 metabolites in cluster III were significantly increased including aspartic acid, 4-hydroxyproline, ornithine, and fructose, while 12 were significantly decreased. In cluster IV, 5-hydroxyindole-3-acetic acid and nicotinamide were increased in 10D6 group but decreased in 20D6 and 40D6 groups. On the contrary, hexanoic acid was decreased in 10D6 but increased in 20D6 and 40D6 groups. Interestingly, glycolic acid was increased in 20D6 but decreased in both 10D6 and 40D6 groups.
All the rest was consistently decreased in the 3 groups. In cluster V, alanine, creatinine, glutamine, and histidine were steadily upregulated in 20D6 and 40D6 groups. The fold change of 3-hydroxyphenylpropionic in AA-treated groups was increased but showed no statistical significance with univariate statistics. Inosine was upregulated in 20D6, but significantly decreased in 40D6 group, whereas the rest 8 metabolites were significantly downregulated in both 20D6 and 40D6 groups. In cluster VI, 6 out of the 17 metabolites were greatly increased in 40D6 group such as leucine, glycine, threonine, aminomalonic acid, aspartic acid, and fructose, while most of the rest were significantly decreased in 40D6 group, except for benzoic acid and lysine that were increased in fold change but without statistical significance. In summary, the alteration of the metabolites in cluster I-VI indicated the time-or dose-dependent metabolic changes induced by AA treatment, and detailed description of these metabolites was presented in Supplementary Tables 2 and 3 .
FIG. 2. Histological analysis of kidney in rats.
Black arrows indicate the presence of cellular necrosis and damage of cortical renal tubules. Con2, Con4, and Con6 represent control rats on the 2nd, 4th, and 6th day, respectively. In total, 10D2, 10D4, and 10D6 represent rats treated with 10 mg/kg AA for 2, 4, and 6 days, respectively. In total, 20D2, 20D4, and 20D6 represent rats treated with 20 mg/kg AA for 2, 4, and 6 days, respectively. In total, 40D2, 40D4, and 40D6 represent rats treated with 40 mg/kg AA for 2, 4, and 6 days, respectively.
The Alteration of Metabolic Pathways in AA-Treated Rats
The involved metabolic pathways were further mapped with identified time-or dose-dependently altered metabolites. The 18, 6, and 21 time-dependent differential metabolites (clusters of I-III described in Supplementary Table 2) were mapped into 11, 7, and 17 pathways, respectively ( Figure 5A ). It showed that several metabolic pathways were altered in all of three 40 mg/kg AA groups such as pathways (cluster I) involved amino acids metabolism, nitrogen metabolism, and nicotinate and nicotinamide metabolism. Pathways involved in branch-chain amino acids, glycerophospholipids, and galactose metabolism were altered in 40D4 and 40D6 groups (cluster II). Some metabolic pathways were only disturbed in 40D6 group (cluster III) such as amino acids metabolism (including alanine, asparate, glutamate, tyrosine, beta-alanine, phenylalanine, and tryptophan metabolism), carbohydrate, propanoate and glutathione metabolism, pantothenate and CoA biosynthesis, and amino sugar and nucleiotide sugar metabolism. In addition, some metabolic pathways were enriched with metabolites from more than 1 clusters, e.g. pathways of TCA cycle, arginine, proline, glyoxylate and dicarboxylate metabolism, and purine metabolism were enriched with metabolites from clusters I to III; pathways of amino acyl-tRNA biosynthesis and glycerolipid metabolism with metabolites from clusters I to II, as well as pathway of pyrimide metabolism with metabolites from clusters I to III ( Figure 5A ). The metabolic pathways characterizing the dose-dependent impacts of AA were analyzed with the 8, 14, and 17 dosedependent differential metabolites among groups of 10D6, 20D6, and 40D6 (clusters of IV-VI described in Supplementary  Table 3) . A total of 6, 14, and 19 pathways were mapped, respectively ( Figure 5B) . Consistent with the appearance of nephrotoxicity, a variety of disturbed metabolic pathways were enriched in 40D6 group such as pathways of TCA cycle, cyanomino acid, amino acids, glutathione, amino sugar and nucleiotide sugar metabolism, carbohydrate, and ascorbate metabolism (cluster VI). Many pathways were involved in both 20D6 and 40D6 groups such as pathways of amino acids (including arginine, proline, beta-alanine, glutamine, glutamate, and histidine metabolism), propanoate metabolism, and glycerolipid metabolism (cluster V). Pathways of tryptophan and glycerophospholipids metabolism were disturbed in all 10D6, 20D6, and 40D6 groups (clusters IV). Several metabolic pathways were enriched with metabolites from more than 1 clusters, such as pyrimidine and purine metabolism pathways with metabolites from clusters of IV to V, aminoacyl-tRNA biosynthesis, amino acids (including glycine, serine, threonine, alanine, asparate, and glutamate) metabolism, and nitrogen metabolism from clusters of V to VI, as well with all identified metabolites among groups on the 2nd, 4th, and 6th day with SIMCA-P software. Each point represents the metabolic profile of 1 mouse. PC1 and PC2 represent the first and second principal components in the model, respectively. as glyoxylate and dicarboxylate metabolism pathways from clusters of IVV to VI ( Figure 5B ).
Selection of Potential Metabolic Biomarkers for AA-Induced Nephrotoxicity
Among the identified differential metabolites, 8 metabolites were selected as potential metabolic biomarkers according to the criteria of both VIP > 1.5 and P < .001 described in method including methylsuccinic acid, nicotinamide, uric acid, creatinine, 3-hydroxyphenylacetic acid, citric acid, glycolic acid, and gluconic acid (Figure 6 ). Among these 8 metabolites, we observed 4 of them were changed dose-dependently including methylsuccinic acid, creatinine, 3-hydroxyphenylacetic acid, and citric acid. Except for the increased creatinine, the relative concentration of methylsuccinic acid, 3-hydroxyphenylacetic acid, and citric acid was decreased dose-dependently, and dramatic reduction was present on the 2nd day and maintained at similar levels to the 6th day in 40 mg/kg AA group, which was earlier than the occurrence of conventional biomarkers of nephrotoxicity. The urinary creatinine was steadily upregulated from 10D6 to 40D6. Therefore, we speculated that the urinary variation of methylsuccinic acid, 3-hydroxyphenylacetic acid, citric acid, and creatinine might serve as potential "early metabolic biomarker" for AA-induced nephrotoxicity. Meanwhile, we observed that nicotinamide, uric acid, and gluconic acid showed obvious reduction time-and dose-dependently in AA-treated groups, and the greatest reduction of them consistently appeared in 40D6 group. In addition, obvious reduction of glycolic acid was observed in both 10D6 and 40D6 groups but increased in 20D6 group. It was time-or dose-independently altered by AA treatment. As a result, the variation of nicotinamide, uric acid, and gluconic acid was closely associated with the occurrence of kidney damage and might be "late metabolic biomarker" for AA-induced nephrotoxicity.
DISCUSSION
In this study, global metabolic alterations were observed in AAtreated rats. Plasma creatinine is a commonly used indicator for renal damage. It is believed that the enzymatic method for determining plasma creatinine is not sensitive enough because of the very low level of creatinine in blood (Chan et al., 2008) , as well as the delayed response upon serious renal damage. Chan et al. (2008) observed the metabolic changes in AA-treated rats at different dosages for consecutive 3 days with LC-MS, and the significant urinary metabolic changes were only present in the high-dose (30 mg/kg) group. Meanwhile, the plasma metabolic profile of control rats was separated from AA-treated groups but the separation trend of low-dose (2 mg/kg) group was opposite to those in the middle-(10 mg/kg) and high-dose (30 mg/kg) groups (Lin et al., 2010) , suggesting that the metabolic impacts of AA are dose-dependent on rats. In this study, we found that the urinary creatinine was steadily upregulated by AA treatment in a dose-dependent way, and maintained at high levels from the 2nd to 6th day in 40 mg/kg AA group. Meanwhile, our results also showed the concentration of serum creatinine was significantly increased from the 2nd to 6th day in 40 mg/kg AA group with GC-MS analysis (data not shown), indicating the determination of serum creatinine with GC-MS was more sensitive than traditional enzymatic way. Because the upregulation of creatinine in blood is usually due to the reduced urinary excretion during renal dysfunction, we found that the secretion of urinary creatinine was increased in AA-treated rats. Our results were consistent with the previous report, in which increased urinary creatinine was observed, in addition to blood (Zhao et al., 2015) . Therefore, we speculated that both the production and excretion of creatinine was enhanced in AA-treated rats, and the dose-dependent alteration of urinary creatinine was a potential biomarker for evaluating kidney injury induced by AA treatment, in addition to its upregulation in blood.
Previously, Ni et al. (2007) performed the metabolic profiling on the urine samples from single-dose AA-treated rats with a combined GC-MS and LC-MS approach and identified a total of 15 differential metabolites between AA and control groups mainly involved in TCA cycle, amino acids metabolism, and gut microbiota. In our current study, we totally found 84 and 81 differential metabolites that were significantly altered by AA treatment at different time points and dosages. Moreover, 6 clusters of metabolites were subclassified for characterizing the time-or dose-dependent impacts of AA, as well as the associated metabolic pathways. We speculated that the reasons for the huge differences in number of differential metabolites between Ni et al. (2007) and ours were probably due to the differences in derivatization method prior to GC-MS analysis and the dosages of AA treatment between our studies.
Obvious disturbance in energy metabolism was present in AA-induced nephrotoxicity (Ni et al., 2007; Zhao et al., 2015) . In our current study, we found significant reduction of intermediates in glycolysis, TCA cycle, and metabolites involved in mitochondrial activity such as glyceric acid, glycerol 3-phosphate, citric acid, cisaconitic acid, methylsuccinic acid, and nicotinamide. It has been proposed that the reduction of urinary citric acid is a potential biomarker for renal damage in AA-treated rats (Chan et al., 2008) . Our results showed that urinary citric acid not only significantly decreased in 40D2, 40D4, and 40D6 groups but also was selected as one of the "early potential biomarkers" because of its greatest reduction on the 2nd day of 40 mg/kg AA treatment. These results indicated that the disturbance of TCA cycle was prior to the occurrence of renal injury in 40 mg/kg AA group but the depletion of urinary citric acid might not correlate with the extent of renal injury. In addition, both methylsuccinic acid and 3-hydroxyphenylacetic acid were dose-dependently reduced. The decreased urinary methylsuccinic acid has been observed in d-serineinduced nephrotoxicity in rats (Xiong et al., 2016) . Therefore, the reduction of urinary methylsuccinic acid was probably a metabolic biomarker for renal damage but with no specificity in response to different types of toxins. Nicotinamide is an important component for coenzyme Nicotinamide adenine dinucleotide (NAD) that plays critical roles in energy metabolism through electron transport chain in mitochondria. Ayla et al. (2011) has reported that pretreatment with nicotinamide alleviated the doxorubicin-induced nephrotoxicity via its antioxidant and antiinflammatory action. The urinary levels of nicotinamidein in our study were gradually decreased time-and dose-dependently, suggesting the dysregulation of energy metabolism and mitochondrial damage in AA-induced renal injury.
The variations of gut microbiota-related metabolites have been reported in AA-treated animals such as hippuric acid, hydroxyphenylacetic acid, p-cresol, phenylacetylgycine, and indoxyl sulfate (Ni et al., 2007; Zhao et al., 2015) . We found several gut microbiota-related metabolites were reduced in AA-treated rats such as hippuric acid, 3-hydroxyphenylacetic acid, and 5-hydroxyindole-3-acetic acid, in which FIG. 6 . Selected potential metabolic biomarkers. The potential metabolic biomarkers were selected with the criteria of the P values < .001 and the variable importance in the projection scores (> 1.5) in PLS-DA models.
3-hydroxyphenylacetic acid was further selected as one of the potential metabolic biomarkers. The aromatic metabolites such as 3-hydroxyphenylacetic acid and 3-hydroxyhippuric acid are presumably derived from phenylalanine by Clostridium species (Xiong et al., 2016) . The reduction of urinary 3-hydroxyphenylacetic acid suggested the probable alteration of Clostridium species in AA-treated rats. The reduced 3-hydroxyphenylacetic acid might be a potential "early metabolic biomarker" for AAinduced nephrotoxicity. Another 3 metabolites with the highest significance and contribution to the models were selected as potential metabolic biomarkers including uric acid, glycolic acid, and gluconic acid. Except for the time-or dose-independent change of glycolic acid, uric acid, and gluconic acid showed obviously time-and dose-dependent change in AA-treated groups, which were probably associated with the extent of kidney damage. The alteration of purine metabolism has been observed in AA-treated rats including increase of urinary uric acid and allantoin, an oxidized metabolite of uric acid (Zhao et al., 2015) . Uric acid is produced by enzyme xanthine oxidase from xanthine in purine metabolic pathway and can be oxidized by reactive oxygen species into allantoin, which is also a biomarker for oxidative stress and associated with renal damage (Chen et al., 2016; Kand'ar and Zkaova, 2008; Martens et al., 1987) . Given the fact that increased oxidative stress contributes to AA-induced nephrotoxicity (Bunel et al., 2016; Matsui et al., 2011) , our current results suggested that the time-and dose-dependent depletion of urinary uric acid was due to the transformation of uric acid into allantoin in blood by reactive oxygen species because serum allantoin was increased in AA-treated rats (data not shown). Accordingly, the variations of urinary uric acid, nicotinamide, and gluconic acid could be potential "late metabolic biomarker" for AA-induced nephrotoxicity because of the time-and dosedependent reduction in AA-treated groups.
In summary, our current study indicated that AA treatment resulted in urinary time-or dose-dependent metabolic alterations which were more sensitive than the conventional biomarkers. Eight potential metabolic biomarkers were selected including methylsuccinic acid, nicotinamide, 3-hydroxyphenylacetic acid, citric acid, creatinine, uric acid, glycolic acid, and gluconic acid, in which 4 of them were altered dosedependently including methylsuccinic acid, 3-hydroxyphenylacetic acid, citric acid and creatinine, and 3 were time-and dose-dependently including nicotinamide, uric acid, and gluconic acid. A group of potential "early metabolic biomarker" was proposed including methylsuccinic acid, 3-hydroxyphenylacetic acid, citric acid, and creatinine on the basis of their great alteration on the 2nd day in 40 mg/kg group, as well as the "late metabolic biomarker" including nicotinamide, uric acid, glycolic acid, and gluconic acid. Nevertheless, further investigations are warranted to validate the relationship between the potential metabolic biomarkers and AA-induced nephrotoxicity, as well as their biological roles in AA-induced nephrotoxicity.
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